大又大又粗又硬又爽少妇毛片,国产亚洲熟妇在线视频,日日碰狠狠躁久久躁综合网,欧美成人无码A片免费一区澳门

Keryx Biopharmaceuticals  
專注于收購，開發(fā)和商業(yè)化的醫(yī)學治療腎臟疾病的重要醫(yī)藥產品。

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."